Marvin R. Garovoy, Sausalito, CA (US); Peter E. Haroldsen, Pacifica, CA (US); and Donald G. Musson, Larkspur, CA (US)
Assigned to SERB SA, Brussels (BE)
Filed by SERB SA, Brussels (BE)
Filed on May 23, 2023, as Appl. No. 18/322,474.
Application 18/322,474 is a continuation of application No. 17/686,895, filed on Mar. 4, 2022.
Application 17/686,895 is a continuation of application No. 17/503,190, filed on Oct. 15, 2021, granted, now 11,268,128, issued on Mar. 8, 2022.
Application 17/503,190 is a continuation of application No. 17/345,975, filed on Jun. 11, 2021, abandoned.
Application 17/345,975 is a continuation of application No. 17/009,250, filed on Sep. 1, 2020, granted, now 11,060,128, issued on Jul. 13, 2021.
Application 17/009,250 is a continuation of application No. 14/128,672, granted, now 10,793,893, issued on Oct. 6, 2020, previously published as PCT/US2012/044904, filed on Jun. 29, 2012.
Claims priority of provisional application 61/553,045, filed on Oct. 28, 2011.
Claims priority of provisional application 61/503,553, filed on Jun. 30, 2011.
Prior Publication US 2023/0313265 A1, Oct. 5, 2023
1. A method of treating a human patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) in need of treatment thereof comprising administering under fed conditions a total daily dose of about 7.5 mg to about 40 mg of 3,4-diaminopyridine (3,4-DAP), or an equivalent amount of a pharmaceutically acceptable salt thereof, to a human patient diagnosed with LEMS who is a N-acetyl transferase 2 (NAT2) slow acetylator, wherein the total daily dose is optionally provided as a series of divided doses.